In Chicago, 22-25 April, is an annual international forum BIO International Convention 2013, the largest exhibition in the field of biotechnology and the Congress of specialists working in the biotechnology industry. One of the main topics of the meeting this year was Russia: implementation of it strategy "Pharma 2020" and the transformation of the country from developing in the fast-growing pharmaceutical market.
In the special session, devoted to Russia, was attended by representatives Committee on science and high technology and the Committee on health of the State Duma of the Russian Federation, Ministry of economic development, Ministry of industry and trade of the Russian Federation, leaders of the Russian market of biotechnology and representatives of state development institutions.
One of the international experts on Russia, which opened its reports the session, acted as senior Vice President, region Director of emerging markets, GlaxoSmithKline, Rogerio Ribeiro. GlaxoSmithKline, the products of which more than 30 years on the Russian market, is a reliable partner of the Russian state in the development of the healthcare and pharmaceutical industry in the country, primarily in the production of vaccines, Oncology and antiviral drugs. GlaxoSmithKline is a leading international companies operating on the Russian market of vaccines. The company is also one of the leaders in areas related to research new vaccines in Russia.
The session reviewed the prospects of biotechnological trends in the Pharma 2020 strategy", cooperation in the field of immunization, questions-Russia partnership with the global biotech community, technology transfer, development of biotechnology clusters.
Russia was represented at the BIO International Convention for the third time. Participation in this forum aims to present itself as a country that is moving along the path of intensive development of the pharmaceutical industry and, in particular, its biotechnological areas.
BIO International Convention is the largest annual Congress in biotechnology, which provides unique opportunities for networking, building alliances and partnerships, engage in professional discussions about the major trends that are shaping the development of biotechnology in the world, making recommendations for business players in key markets. Participants of the forum in 2013 were more than 15 thousand industry representatives from 65 countries: biotechnology companies, research organizations, state institutions and international organizations.